LUMINA - LUng Modeling and INtelligence for Advanced care: A Digital Twin Approach to Lung Cancer Diagnosis and Treatment
LUMINA - LUng Modeling and INtelligence for Advanced care: A Digital Twin Approach to Lung Cancer Diagnosis and Treatment

The LUMINA project - Lung Modelling and Intelligence for Advanced Care: A Digital Twin Approach to Lung Cancer Diagnosis and Treatment - addresses the challenge of diagnosing and treating lung cancer by developing advanced artificial intelligence models and personalised digital twins of the lung.
Funded by the European Innovation Council's EIC Pathfinder Challenges programme, this initiative unites an international consortium of European academic and clinical partners, including Aalborg University (the coordinator), Humanitas Research Hospital/Humanitas AI Centre, Politecnico di Milano, Cracow University of Technology, the Maria Skłodowska-Curie National Research Institute of Oncology, and Region Hovedstaden.
The project aims to improve the early diagnosis and risk stratification of lung cancer, as well as the personalisation of cancer therapies, by developing a lung digital twin that integrates longitudinal and multimodal clinical data, including CT scans, electronic health records, laboratory tests and treatment history, to model disease progression and response to treatments.
The Department of Management, Economics and Industrial Engineering of Politecnico di Milano, led by Emanuele Lettieri and Maria Pinelli, will focus on evaluating and exploiting the innovations developed within the project. The DIG team will contribute to:
- The multidimensional impact assessment of AI-based innovations developed within LUMINA using the Health Technology Assessment (HTA) methodology
- The exploitation of these results aims to promote the transferability, adoption and commercialisation of AI-based innovations within European healthcare systems.
LUMINA thus aims to lay the scientific and technological foundations for a new generation of AI-based clinical tools that can support more precise and personalised decisions throughout the entire lung cancer care pathway.